Latest news with #AnjeeDavis
Business Upturn
2 days ago
- Business
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 days ago
- Health
- Yahoo
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in to access your portfolio
Yahoo
27-05-2025
- General
- Yahoo
Global Experts from 23 Countries Convene in Barcelona to Confront Rising Rates of Early Onset Colorectal Cancer
Global Early Onset Colorectal Cancer Think Tank Springfield, Mo., May 27, 2025 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), in partnership with Dr. José Perea of the Instituto de Investigación Biomédica de Salamanca (IBSAL) and a global network of collaborators, will host the inaugural Global Early Onset Colorectal Cancer Think Tank (GEOCRCTT) on June 18–19 in Barcelona, Spain. This two-day event will convene leading experts from research, healthcare, and advocacy to develop a comprehensive research strategy aimed at reversing the troubling trend in early onset colorectal cancer (EOCRC) cases. 'It's the first time we've ever hosted an international meeting, and we are thrilled to convene more than 75 scientists and patients,' said Anjee Davis, CEO of Fight CRC. 'Global partners consistently ask us, 'How can we meaningfully engage patients and reflect their voices in the science?' Through this international coalition of scientists, we're committed to advancing the science with patients at the center. We want to make sure the lessons we've learned in the U.S. are shared globally. This isn't just about presenting research; it's about rolling up our sleeves and working together to drive it forward. It's a true dialogue around collaboration, and that level of global partnership simply hasn't happened before.' As early onset colorectal cancer becomes increasingly prevalent, especially in countries with traditionally lower risk, the GEOCRCTT represents a timely and necessary response. Through keynote speeches, interactive panel discussions, and specialized breakout sessions, the Think Tank will facilitate knowledge sharing across borders and disciplines. Experts will focus on setting research priorities, strengthening collaborative efforts, and identifying targeted ways to support patients, caregivers, and affected communities worldwide. 'This gathering marks a pivotal moment in our approach to early onset colorectal cancer research as one of the only initiatives to explore global etiology; not just from a specific country or region, the entire world,' said Andrea (Andi) Dwyer, advisor to Fight CRC and member of the University of Colorado Cancer Center. "The future of EOCRC research and patient support depends on this level of unity and commitment.' The GEOCRCTT reflects the growing urgency to address EOCRC with a united, strategic approach. For more information on the GEOCRCTT, or to support Fight Colorectal Cancer and its partners, visit or join the conversation at #GEOCRCTT. GEOCRCTT Goals and Deliverables: Publishing Think Tank Outcomes: Findings, recommendations, and action items will be published in a leading peer-reviewed journal, making them accessible to the global research and medical communities. Supporting Critical Research Efforts: Through GEOCRCTT, six grants have been awarded to support baseline data collection internationally. This research funding underscores a united commitment to filling gaps in understanding EOCRC's causes, risk factors, and trends on an international scale. Empowering Patients and Advocates: Through focused sessions, GEOCRCTT will provide advocacy groups and patient communities with the latest information and strategies to elevate awareness and improve support networks globally. Fight CRC remains committed to advancing these efforts and fostering a global culture of informed, patient-centered care. Attachment Global Early Onset Colorectal Cancer Think Tank CONTACT: Savanna Doud Fight Colorectal Cancer 703-548-1225 media@
Yahoo
03-04-2025
- Health
- Yahoo
Scientists sound warning over Trump cuts — and 75% consider leaving the U.S.
This week, in response to President Trump's ongoing cuts to scientific research and staffing at federal agencies, nearly 2,000 of the country's leading scientists signed a letter urging the administration to 'cease its wholesale assault on U.S. science.' 'We see real danger in this moment,' the letter, which was signed by a number of Nobel Prize winners, stated. 'We hold diverse political beliefs, but we are united as researchers in wanting to protect independent scientific inquiry. We are sending this SOS to sound a clear warning: the nation's scientific enterprise is being decimated.' Last week, the journal Nature published a poll it conducted of more than 1,600 U.S. scientists. 'Are you a US researcher who is considering leaving the country following the disruptions to science prompted by the Trump administration?' the poll asked the group. In response, 75.3% of those polled said yes, while 24.7% said no. The poll was conducted prior to Tuesday's announcement by the Department of Health and Human Services that it was laying off 10,000 employees, including scientists from agencies such as the Food and Drug Administration and the National Cancer Institute, among others. The mass firing followed Trump administration cuts to research funded by the National Institutes of Health. 'We're scared that these blanket mandates could erase decades of progress fighting cancer,' Anjee Davis, the CEO of Fight Colorectal Cancer, a patient advocacy group, told CBS News. 'This isn't about politics. It's about protecting the progress we've fought so hard to achieve in cancer care and research over the past two decades.' In a post to social media on Tuesday, HHS Secretary Robert F. Kennedy Jr. described the job and funding cuts as a way to improve health outcomes. 'This overhaul is about realigning HHS with its core mission: to stop the chronic disease epidemic and Make America Healthy Again,' Kennedy wrote. 'It's a win-win for taxpayers, and for every American we serve.' Former FDA Commissioner David Kessler sharply disagreed. 'We are less safe today because of these cuts that have happened the last several days,' Kessler said in a Wednesday interview with MSNBC. 'I always thought that things were fixable. You could fix things. I am very concerned that if these cuts are not rescinded, these will have an effect for decades.' On Wednesday, the American Civil Liberties Union filed a lawsuit against NIH on behalf of several scientists laid off in the HHS purge. 'Our case is specifically addressing NIH's lawless grant terminations and their upending of the grant review process for applicants,' Olga Akselrod, senior counsel at the ACLU Racial Justice Program, told NBC News. 'These sweeping actions have disrupted hundreds of research grants, derailed really crucial research and are upending the careers of the most promising scientists in the United States with really no clear rationale.' While the Trump administration has taken a dim view of federal science spending, cutting agencies like the Environmental Protection Agency, the National Oceanic and Atmospheric Association and the National Weather Service, a 2023 paper published by the Federal Reserve Bank of Dallas found that government research and development funding accounted for more than one-fifth of U.S. productivity growth over the last 80 years. 'For over 80 years, wise investments by the US government have built up the nation's research enterprise, making it the envy of the world,' the letter sent this week from the nearly 2,000 scientists stated. 'Astoundingly, the Trump administration is destabilizing this enterprise by gutting funding for research, firing thousands of scientists, removing public access to scientific data, and pressuring researchers to alter or abandon their work on ideological grounds.'
